M. Pensiero

发表

Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.

J. K. Pullen, B. Weniger, Ian E. Anglin, 2018, Vaccine.

Current advances and challenges in HIV-1 vaccines

J. Bradac, E. Hill, M. Pensiero, 2006, Current HIV/AIDS reports.

Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC).

N. Young, E. Read, S. Leitman, 1999, Human gene therapy.

Purified, Soluble Recombinant Mouse Hepatitis Virus Receptor, Bgp1b, and Bgp2 Murine Coronavirus Receptors Differ in Mouse Hepatitis Virus Binding and Neutralizing Activities

G. Dveksler, F. Phibbs, B. Zelus, 1998, Journal of Virology.

Mouse hepatitis virus strain A59 and blocking antireceptor monoclonal antibody bind to the N-terminal domain of cellular receptor.

C. Dieffenbach, G. Dveksler, K. Holmes, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Hantaan virus infection of human endothelial cells

C. Dieffenbach, J. Hay, J. Sharefkin, 1992, Journal of virology.

Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum.

C. Wysocki, M. Pensiero, G. Kikuchi, 1996, Human gene therapy.

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period

D. Montefiori, S. Kalams, M. McElrath, 2019, The Journal of infectious diseases.

Speci ﬁ city and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modi ﬁ ed Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

S. Hammer, B. Moss, S. Buchbinder, 2014 .

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

D. Montefiori, M. McElrath, P. Goepfert, 2011, Vaccine.

Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation.

R. Schiffmann, S. Karlsson, R. Brady, 1998, Human gene therapy.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

J. Kublin, D. Montefiori, N. Frahm, 2018, The lancet. HIV.

The Hantaan virus M-segment glycoproteins G1 and G2 can be expressed independently

J. Hay, M. Pensiero, M. N. Pensiero, 1992, Journal of virology.

DEVELOPMENT OF VIRAL VECTORS FOR HUMAN GENE THERAPY: RETROVIRUS AND ADENOVIRUS (pART I)

B. Trapnell, M. Pensiero, 1997 .

Evidence for the presence of an inhibitor on ribosomes in mouse L cells infected with mengovirus

M. Pensiero, J. Lucas-Lenard, 1985, Journal of virology.

Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV

C. Dieffenbach, G. Dveksler, K. Holmes, 1991, Journal of virology.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Donald K Carter, Ian Frank, Beryl Koblin, 2013, The Journal of infectious diseases.

A possible role for glycoprotein gpV in the pathogenesis of varicella-zoster virus.

P. Kinchington, P. Ling, W. Ruyechan, 1990, Advances in experimental medicine and biology.

The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka)

B. Moss, P. Kinchington, P. Ling, 1990, Journal of virology.

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

J. Fuchs, S. Kalams, N. Frahm, 2015, Open forum infectious diseases.

Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant

C. Schmaljohn, J. Hay, G. Jennings, 1988, Journal of virology.

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

J. Kublin, D. Montefiori, L. Morris, 2016, PloS one.

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap

D. Montefiori, L. Morris, C. Williamson, 2016, Clinical and Vaccine Immunology.

Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C gag Vaccine in Healthy HIV-1-Uninfected Adults

D. Burke, N. Russell, S. A. Abdool Karim, 2012, Clinical and Vaccine Immunology.

Several members of the mouse carcinoembryonic antigen-related glycoprotein family are functional receptors for the coronavirus mouse hepatitis virus-A59

N. Beauchemin, C. Dieffenbach, G. Dveksler, 1993, Journal of virology.

Recent advances in humanized mice: accelerating the development of an HIV vaccine.

Todd M. Allen, A. Tager, M. Pensiero, 2013, The Journal of infectious diseases.

Binding of the coronavirus mouse hepatitis virus A59 to its receptor expressed from a recombinant vaccinia virus depends on posttranslational processing of the receptor glycoprotein

C. Dieffenbach, G. Dveksler, K. Holmes, 1992, Journal of virology.

Now that you want to take your HIV/AIDS vaccine/biological product research concept into the clinic: what are the "cGMP"?

J. K. Pullen, S. Shapiro, V. Mehra, 2015, Vaccine.

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

B. Korber, B. Haynes, D. Montefiori, 2023, The Journal of clinical investigation.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

S. Hammer, B. Moss, D. Montefiori, 2014, The Journal of infectious diseases.

Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research

H. Liao, B. Haynes, S. Zolla-Pazner, 2015, Journal of Virology.

Breeding of retroviruses by DNA shuffling for improved stability and processing yields

W. Stemmer, E. Otto, Willem P.C. Stemmer, 2000, Nature Biotechnology.

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

Rachel L. Spreng, P. Gilbert, L. Corey, 2020, Scientific Reports.

Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.

D. Montefiori, I. Frank, G. Ferrari, 2023, Vaccine.

Identification and characterization of the herpes simplex virus type 1 protein encoded by the UL37 open reading frame

F. Jenkins, M. Pensiero, L. Shelton, 1990, Journal of virology.

Robust antibody and cellular responses induced by DNA-only vaccination for HIV.

N. Sardesai, D. Weiner, Jian Yan, 2020, JCI insight.

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

J. Kublin, D. Montefiori, N. Frahm, 2020, PLoS medicine.

Neutralizing Activities in Mouse Hepatitis Virus Binding and Differ Bgp2 Murine Coronavirus Receptors , and b Hepatitis Virus Receptor, Bgp1 Purified, Soluble Recombinant Mouse

G. Dveksler, F. Phibbs, B. Zelus, 2014 .

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

J. Kublin, J. Fuchs, N. Sardesai, 2013, The Journal of infectious diseases.